longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

OPRX

OPRX
8.5702.15%( +0.180 )

LongbridgeAI

OptimizeRx appoints former J&J commercial data science chief Troy Sarich as adviser

PUBT
Sep 2, 2026 at 11:31 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

OptimizeRx has appointed Troy Sarich, former Chief Commercial Data Science Officer at Johnson & Johnson, as a company advisor. Sarich brings extensive experience in data, analytics, and AI across various therapeutic areas including cardiology and oncology. This appointment aims to support OptimizeRx's expansion of technology and data offerings for life sciences marketing.

  • OptimizeRx appointed Troy Sarich as a company advisor. * Sarich previously served as Chief Commercial Data Science Officer at Johnson & Johnson, focusing on data, analytics, and AI. * His background includes roles spanning R&D and commercialization across cardiology, oncology, immunology, and neuroscience. * The appointment supports OptimizeRx’s expansion of its technology and data offerings for life sciences marketing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020730PRIMZONEFULLFEED9819510) on September 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Login to unlock553characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

OptimizeRx

OptimizeRx

USOPRX

+2.15%

Johnson & Johnson

Johnson & Johnson

USJNJ